News Search Results
Jul 31, 2025, 22:02 ET GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
continue to push the boundaries and drive sustainable growth of the industry, aligning with our mission to 'Make People and Nature Healthier through Biotechnology'." The ongoing global recognition of GenScript's sustainability initiatives underscores its commitment to responsible business practices.
More news about: GenScript Biotech Corporation
Jul 31, 2025, 18:00 ET Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Jul 31, 2025, 16:08 ET Human Longevity Extends $1M Cancer Pledge to Lung Cancer--Betting Big on AI-Driven Early Detection
https://www.humanlongevity.com/1mlung Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health
More news about: Human Longevity, Inc.
Jul 31, 2025, 16:01 ET AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jul 31, 2025, 13:55 ET QuantiPath Adds Top-Tier Executives to Leadership Team Ahead of GenoPATHx Launch
DENVER, July 31, 2025 /PRNewswire/ -- QuantiPath.bio, a biotechnology company redefining food safety through precision genetic diagnostics, today announced the addition of two accomplished professionals to its executive
More news about: QuantiPath
Jul 31, 2025, 13:35 ET MUSE Global School Opens in Santa Monica, Launching Vibrant New Chapter on the Westside
integration of MICA enhances the school's focus on individualized and collaborative learning. Whether diving into robotics, environmental science, or biotechnology, students can pursue their interests while developing tangible skills for the future. As Dr. Hunter advocates, MICA helps students "march across
More news about: MUSE Global School
Jul 31, 2025, 12:55 ET Tycko & Zavareei LLP: Cybersecurity Whistleblower receives $1.9 Million Reward of Nearly $10 Million False Claims Act Qui Tam Case Against a Biotechnology Company
Illumina, Inc., an American publicly traded biotechnology company, which develops and manufactures products related to genetic testing and research. A copy of the Whistleblower (Relator) Team's complaint
More news about: Tycko & Zavareei LLP
Jul 31, 2025, 10:45 ET Contract Research Organization Market is Poised to Reach USD 122.2 Billion by 2032 | SkyQuest Technology Consulting
chronic illnesses. The need for effective treatments is growing along with the number of chronic illnesses, which motivates pharmaceutical and biotechnology companies to develop new drugs.
More news about: SkyQuest Technology
Jul 31, 2025, 10:30 ET Cell Culture Market worth US$50.69 billion by 2030 with 11.2% CAGR | MarketsandMarkets™
users, the cell culture market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and other end users. The pharmaceutical & biotechnology companies' segment is estimated to register the highest growth rate during
More news about: MarketsandMarkets
Jul 31, 2025, 10:15 ET Biopharmaceuticals Market is Estimated to Reach USD 948.6 Bilion by 2032 | SkyQuest Technology Consulting
The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug development. Due to developments in gene therapies, vaccines, monoclonal antibodies, and next-generation biologics, treatment paradigms are shifting in a variety of therapeutic
More news about: SkyQuest Technology
Jul 31, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers - FTRE
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The Company claims to have the "scale and expertise to advise, design and deliver [its] customers' programs, projects
More news about: Pomerantz LLP
Jul 31, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Jul 31, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Jul 31, 2025, 09:00 ET Mars doubles down on pursuit of perfect peanut, investing $5M in pioneering agri-science
University of Georgia Tifton Campus, HudsonAlpha Institute for Biotechnology and the USDA Agricultural Research Service (ARS).Develop disease-resistant peanut varieties in partnership with USDA ARS, HudsonAlpha Institute for Biotechnology and the National Institute of Agricultural Technology (INTA).Use
More news about: Mars, Incorporated
Jul 31, 2025, 07:44 ET AbbVie Reports Second-Quarter 2025 Financial Results
approved indications, and no new safety signals were identified in this study. AbbVie and Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using targeted lipid nanoparticles (tLNPs), announced a definitive
More news about: AbbVie
Jul 31, 2025, 07:30 ET Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Jul 31, 2025, 07:05 ET REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jul 31, 2025, 07:00 ET Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board
Mass., July 31, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the appointment
More news about: Marengo Therapeutics
Jul 31, 2025, 06:45 ET Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 31, 2025, 06:00 ET ESTEVE CDMO Acquires Regis Technologies, expanding U.S. presence and capabilities
at the heart of everything it does. About Regis Technologies Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization
More news about: ESTEVE
Jul 31, 2025, 04:24 ET ESTEVE Acquires Regis Technologies, expanding U.S. presence and capabilities
at the heart of everything it does. About Regis Technologies Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization
More news about: ESTEVE
Jul 31, 2025, 01:23 ET Nscale, Aker and OpenAI to establish Stargate Norway: a 100,000 NVIDIA GPU AI Gigafactory powered by renewable energy in Northern Norway
majority-owned by TRG, a company controlled by Aker's Chairman, Kjell Inge Røkke. Aker's portfolio spans energy, industrial software, renewables, marine biotechnology, and seafood. It is the largest shareholder in several listed and privately held companies, combining deep industrial expertise with financial strength
More news about: Aker ASA
Jul 30, 2025, 22:06 ET INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Plus is a life sciences software and consulting company that provides advanced biosimulation tools and consulting services to pharmaceutical and biotechnology companies worldwide. THE ALLEGED WRONGDOING: On July 14, 2025, Simulations Plus reported
More news about: Edelson Lechtzin LLP
Jul 30, 2025, 13:58 ET ARCHIMED Acquires a Majority Stake in Arkstone, Forging a Powerful Partnership to Accelerate Global Healthcare Innovation And Dominate the Emerging AI-Driven Clinical Decision Support Market
Arkstone, an innovative biotechnology company democratizing infectious disease expertise and fighting antimicrobial resistance, has been acquired by global healthcare private equity firm ARCHIMED, which now holds a majority stake. BOCA
More news about: Arkstone
Jul 30, 2025, 11:22 ET Robbins LLP Reminds CAPR Investors with Large Losses of the Class Action Lawsuit on Behalf of Capricor Therapeutics, Inc. Shareholders
securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating
More news about: Robbins LLP